Humer Franz B 4
4 · Allogene Therapeutics, Inc. · Filed Oct 17, 2018
Insider Transaction Report
Form 4
Humer Franz B
Director
Transactions
- Purchase
Common Stock
2018-10-15$18.00/sh+30,000$540,000→ 30,000 total - Conversion
Series A Convertible Preferred Stock
2018-10-15−14,261→ 0 total→ Common Stock (74,870 underlying) - Conversion
Common Stock
2018-10-15+74,870→ 104,870 total
Footnotes (1)
- [F1]The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date.